2/25
12:58 pm
bbio
BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target lowered by Oppenheimer Holdings, Inc. from $83.00 to $81.00. They now have an "outperform" rating on the stock.
2/25
12:58 pm
bbio
BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $86.00 to $95.00. They now have a "buy" rating on the stock.
2/25
10:46 am
bbio
BridgeBio Pharma (BBIO) had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an "overweight" rating on the stock.
Medium
Report
BridgeBio Pharma (BBIO) had its price target raised by Morgan Stanley from $96.00 to $98.00. They now have an "overweight" rating on the stock.
2/25
12:27 am
bbio
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/24
06:47 pm
bbio
BridgeBio Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
04:32 pm
bbio
BridgeBio Pharma: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
BridgeBio Pharma: Q4 Earnings Snapshot [Yahoo! Finance]
2/24
04:01 pm
bbio
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
Medium
Report
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
2/23
07:30 am
bbio
BridgeBio to Participate in March Investor Conferences
Low
Report
BridgeBio to Participate in March Investor Conferences
2/17
06:22 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/17
08:03 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
2/17
07:30 am
bbio
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
Low
Report
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
2/13
10:41 pm
bbio
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia [Yahoo! Finance]
Low
Report
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia [Yahoo! Finance]
2/13
10:37 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $81.00 to $83.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $81.00 to $83.00. They now have an "outperform" rating on the stock.
2/13
09:47 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $88.00 to $98.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $88.00 to $98.00. They now have an "overweight" rating on the stock.
2/12
04:37 pm
bbio
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO [FOX Business Network]
Medium
Report
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO [FOX Business Network]
2/12
03:06 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) was given a new $89.00 price target on by analysts at Raymond James Financial, Inc.. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) was given a new $89.00 price target on by analysts at Raymond James Financial, Inc.. They now have an "outperform" rating on the stock.
2/12
07:30 am
bbio
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
Low
Report
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
1/29
07:02 pm
bbio
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility [Yahoo! Finance]
1/28
08:00 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/27
05:10 pm
bbio
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/27
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/20
10:52 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $84.00 to $88.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $84.00 to $88.00. They now have an "overweight" rating on the stock.
1/16
01:00 am
bbio
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Low
Report
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
1/15
11:32 am
bbio
BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
Low
Report
BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
1/15
06:21 am
bbio
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]
Low
Report
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]